Daniel El Fassi

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves’ Disease: A Controlled Pilot Study

Daniel El Fassi, Claus Henrik Nielsen, Steen Joop Bonnema et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 153 citations · Full text

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen et al. · Haematologica · 2019 · 103 citations · Full text

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Daniel El Fassi, J. Paul Banga, Jacqueline A. Gilbert et al. · Clinical Immunology · 2008 · 89 citations

Allergy, Autoimmune Disease, Thyroid Disease +6

Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial

Camilla Fuchs Andersen, Massar Omar, Andreas Glenthøj et al. · European Journal of Heart Failure · 2022 · 69 citations · Full text